Brokerages expect Immune Design Corp. (NASDAQ:IMDZ) to report sales of $620,000.00 for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Immune Design Corp.’s earnings, with estimates ranging from $400,000.00 to $840,000.00. Immune Design Corp. posted sales of $8.21 million during the same quarter last year, which would indicate a negative year over year growth rate of 92.4%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, November 8th.
According to Zacks, analysts expect that Immune Design Corp. will report full year sales of $620,000.00 for the current year, with estimates ranging from $7.00 million to $11.00 million. For the next year, analysts expect that the business will report sales of $16.54 million per share, with estimates ranging from $15.08 million to $18.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Immune Design Corp..
Immune Design Corp. (NASDAQ:IMDZ) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.11. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. The business had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $1.50 million.
A number of equities analysts recently issued reports on the company. ValuEngine downgraded Immune Design Corp. from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Royal Bank Of Canada assumed coverage on Immune Design Corp. in a report on Thursday, September 14th. They issued an “outperform” rating and a $20.00 price target for the company. BidaskClub downgraded Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 5th. Zacks Investment Research raised Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a report on Tuesday, July 18th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $18.00 price target on shares of Immune Design Corp. in a report on Wednesday, June 28th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Immune Design Corp. currently has a consensus rating of “Buy” and an average price target of $16.33.
TRADEMARK VIOLATION WARNING: “$620,000.00 in Sales Expected for Immune Design Corp. (IMDZ) This Quarter” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://stocknewstimes.com/2017/10/08/620000-00-in-sales-expected-for-immune-design-corp-imdz-this-quarter.html.
Immune Design Corp. (NASDAQ:IMDZ) traded down 4.11% during mid-day trading on Thursday, hitting $10.50. 133,709 shares of the stock were exchanged. Immune Design Corp. has a 12-month low of $4.50 and a 12-month high of $13.05. The company has a 50 day moving average of $9.96 and a 200 day moving average of $8.40. The firm’s market cap is $269.00 million.
In other Immune Design Corp. news, Director Lewis W. Coleman purchased 12,000 shares of the stock in a transaction that occurred on Tuesday, July 11th. The stock was purchased at an average cost of $9.05 per share, with a total value of $108,600.00. Following the completion of the acquisition, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $362,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Lewis W. Coleman purchased 10,000 shares of the stock in a transaction that occurred on Monday, July 10th. The stock was acquired at an average cost of $9.00 per share, with a total value of $90,000.00. Following the completion of the acquisition, the director now directly owns 40,000 shares of the company’s stock, valued at $360,000. The disclosure for this purchase can be found here. Insiders purchased 32,000 shares of company stock valued at $295,600 over the last ninety days. 20.70% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System boosted its holdings in Immune Design Corp. by 8.3% in the second quarter. California State Teachers Retirement System now owns 30,174 shares of the biotechnology company’s stock valued at $294,000 after purchasing an additional 2,300 shares in the last quarter. Sectoral Asset Management Inc acquired a new stake in shares of Immune Design Corp. in the second quarter valued at approximately $1,641,000. Goldman Sachs Group Inc. acquired a new stake in shares of Immune Design Corp. in the second quarter valued at approximately $291,000. Numeric Investors LLC acquired a new stake in shares of Immune Design Corp. in the second quarter valued at approximately $1,641,000. Finally, Bain Capital Public Equity Management LLC boosted its holdings in shares of Immune Design Corp. by 393.1% in the second quarter. Bain Capital Public Equity Management LLC now owns 389,400 shares of the biotechnology company’s stock valued at $3,797,000 after acquiring an additional 310,433 shares during the period. 51.46% of the stock is owned by hedge funds and other institutional investors.
About Immune Design Corp.
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.